Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Comment by Hiddensecretson Jun 11, 2021 5:16pm
146 Views
Post# 33376530

RE:RE:Revenue in Q2 +/- $ 12 million

RE:RE:Revenue in Q2 +/- $ 12 millionVery recent presentation by David Preiner, only a few weeks old, forecasted revenue of $ 60 million in 2021.  Forecast was made in late May 2021.

We had revenue of $ 11 million Q1 which means that we need $ 49 million from the other 3 quarters.

David is a very conservative person and he will not throw out numbers out there for the sake of throwning them out.   

When he did the presentation he had an idea of the Q2 revenue run rate and, he  also knew of Q1 results, so for him to make this forecast almost 6 months into the year, 2021 of $ 60 million means that he has a pretty good idea of present sales.

You cannot hit $ 60 million in 2021 if we are only going to make $ 1 million per month on covid19 testing from April 1, 2021 to December 31, 2021, there would be missing another $ 40 million in revenue, which he sees and we do not.

I think it will a combination of factors:   nuturell, adxit, pharmacy, vaccine, hospitals, etc...

Nuturell on its own can generate $ 60 million if it is in hot demand. 

We will know in August 2021.

mpo
<< Previous
Bullboard Posts
Next >>